Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial
CC Thompson, BKA Dayyeh, V Kushnir… - Surgery for Obesity and …, 2019 - Elsevier
Abstract Background The AspireAssist is the first Food and Drug Administration–approved
endoluminal device indicated for treatment of class II and III obesity. Objectives We earlier
reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes. Setting
United States–based, 10-center, randomized controlled trial involving 171 participants with
the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control
arm receiving Lifestyle Therapy (2: 1 randomization). Methods AT participants were …
endoluminal device indicated for treatment of class II and III obesity. Objectives We earlier
reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes. Setting
United States–based, 10-center, randomized controlled trial involving 171 participants with
the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control
arm receiving Lifestyle Therapy (2: 1 randomization). Methods AT participants were …
以上显示的是最相近的搜索结果。 查看全部搜索结果